Combined Treatment with Lenalidomide and Epoetin Alfa Leads to Durable Responses in Patients with Epo-Refractory, Lower Risk Non-Deletion 5q [Del(5q)] MDS: Final Results of the E2905 Intergroup Phase III Study - an ECOG-ACRIN Cancer Research Group Study, Grant CA180820, and the National Cancer Institute of the National Institutes of Health

Timothy R Wassenaar,Alan F List,Jaroslaw P Maciejewski,Zhuoxin Sun,David F Claxton,Martin S Tallman,Rami S Komrokji,Charles A Schiffer,Amit Verma,Kathy Mcgraw,Puneet S Cheema,John M Bennett,Mark Litzow,Andrew S Artz,Selina M Luger,Ryan J Mattison,Jessica K Altman

doi:10.1182/blood-2019-127274

Combined Treatment with Lenalidomide and Epoetin Alfa Leads to Durable Responses in Patients with Epo-Refractory, Lower Risk Non-Deletion 5q [Del(5q)] MDS: Final Results of the E2905 Intergroup Phase III Study - an ECOG-ACRIN Cancer Research Group Study, Grant CA180820, and the National Cancer Institute of the National Institutes of Health

Timothy R Wassenaar, Alan F List + Show 15 more

Open Access

https://doi.org/10.1182/blood-2019-127274

Copy DOI

Journal: Blood	Publication Date: Nov 13, 2019
Citations: 3

Affiliation: Waukesha Memorial Hospital, Moffitt Cancer Center, Cleveland Clinic, Dana-Farber Cancer Institute, Penn State Milton S. Hershey Medical Center, Memorial Sloan Kettering Cancer Center, Karmanos Cancer Institute, Albert Einstein College of Medicine, University of Rochester, Mayo Clinic, University of Chicago, University of Pennsylvania, University of Wisconsin–Madison, Northwestern University

#Advisory Committees #Research Funding + Show 8 more

Abstract
Full-Text PDF
Similar Papers

Abstract

Combined Treatment with Lenalidomide and Epoetin Alfa Leads to Durable Responses in Patients with Epo-Refractory, Lower Risk Non-Deletion 5q [Del(5q)] MDS: Final Results of the E2905 Intergroup Phase III Study - an ECOG-ACRIN Cancer Research Group Study, Grant CA180820, and the National Cancer Institute of the National Institutes of Health

Full Text